Study Drug CC 10004

Sex: Female, Male

Region of Enrollment

The primary efficacy measure was a Global Response Assessment (GRA), a subject completed questionnaire that measures improvement in overall symptoms. The GRA is a 7-point scale the allows the subject to respond to the question: "As compared to when you started the study, overall how do you feel? The responses are: Markedly Improved - 7, Moderately Improved - 6, Mildly Improved - 5, Same - 4, Mildly Worse - 3, Moderately Worse - 2, Markedly Worse - 1.
The primary outcome showing response to treatment was the number of subjects that were moderately or markedly improved on the GRA scale.

Global Response Assessment

Overall Study

Kenneth M. Peters, MD

Vulvodynia

CC-10004

William Beaumont Hospital

CC-10004 For The Treatment Of Vulvodynia

A Clinical Trial Of CC-10004 For The Treatment Of Vulvodynia

Kenneth Peters, MD

Principal Investigator

Celgene Corporation

Interstitial Cystitis

Vulvar Diseases

capsaicin

Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

University of Pittsburgh

vulvar vestibulitis

histamine

vulvar vestibulitis/histamine

CC-10004 For The Treatment Of Vulvodynia

Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı